Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2021 10/13/2021 10/14/2021 10/15/2021 10/18/2021 Date
251.03(c) 253.01(c) 268.57(c) 266.92(c) 262.6 Last
375 073 226 211 620 501 430 440 44 053 Volume
-1.05% +0.79% +6.15% -0.61% -1.62% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 641 M - -
Net income 2021 122 M - -
Net cash position 2021 495 M - -
P/E ratio 2021 125x
Yield 2021 -
Sales 2022 752 M - -
Net income 2022 139 M - -
Net cash position 2022 667 M - -
P/E ratio 2022 112x
Yield 2022 -
Capitalization 14 675 M 14 675 M -
EV / Sales 2021 22,1x
EV / Sales 2022 18,6x
Nbr of Employees -
Free-Float 92,9%
More Financials
Company
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial)... 
More about the company
Ratings of Repligen Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about REPLIGEN CORPORATION
10/14REPLIGEN : Exane BNP Paribas Starts Repligen at Outperform with $330 Price Target
MT
10/14REPLIGEN : to Report Third Quarter 2021 Financial Results
GL
09/27REPLIGEN : Craig Hallum Adjusts Repligen PT to $368 From $258, Maintains Buy Rating
MT
09/17VC DAILY : Question: What's Top of Mind for VCs as the Fourth Quarter Approaches?
DJ
09/17REPLIGEN : KeyBanc Raises Price Target on Repligen to $335 From $255, Keeps Overweight Rat..
MT
09/16REPLIGEN : to Acquire Chromatography Developer Avitide in $150 Million Cash-And-Stock Deal
MT
09/16REPLIGEN : Announces Agreement to Acquire Avitide Inc (Form 8-K)
PU
09/16REPLIGEN CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
09/16Repligen Announces Agreement to Acquire Avitide Inc.
GL
09/16Repligen Corporation agreed to acquire Avitide, Inc. for $150 million.
CI
09/14INSIDER SELL : Repligen
MT
09/10REPLIGEN : and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purifica..
AQ
09/09REPLIGEN : and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purifica..
AQ
09/09Repligen Corporation and Navigo GmbH Announce Launch of Industry-First Protein A Ligand..
CI
09/06REPLIGEN : Extends Long Term Supply Agreement with Cytiva for Affinity Ligands
AQ
More news
News in other languages on REPLIGEN CORPORATION

- No features available -

More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Stock Trading Strategies
REPLIGEN CORPORATION - 07/28
The revival in interest should continue
BUY
More Stock Trading Analysis
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 266,92 $
Average target price 287,78 $
Spread / Average Target 7,81%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION39.29%14 675
ABBOTT LABORATORIES7.31%208 288
MEDTRONIC PLC9.06%171 927
BECTON, DICKINSON AND COMPANY-3.62%69 259
HOYA CORPORATION20.71%55 655
DEXCOM, INC.47.27%52 677